Experts: Ending adequate provision would shut down prescription drug ads

The US Food and Drug Administration’s (FDA) plans to eliminate adequate provision in direct-to-consumer (DTC) prescription drug ads could result in a de facto ban on drug advertising due to the high costs associated with fully publicizing a drug's safety profile and practical limitations of broadcast advertising, according to experts who spoke to Focus. It could also make such ads hard to understand for many consumers.

Adequate provision enabled drugmakers to provide a major statement about a drug’s risks while pointing consumers to the full product labeling elsewhere.

If FDA goes through with issuing such a rule, it will likely face significant opposition to the proposal from the pharmaceutical industry, advertising associations, and broadcasters, the experts said. They also noted that such a restriction could violate the First Amendment.

These comments follow FDA’s announcement last September that it would crack down on pharmaceutical advertising and end what it called the “‘adequate provision’ loophole.” Alongside that announcement, the agency sent thousands of letters to drugmakers calling on them to remove misleading ads and sent more than 100 enforcement letters to drugmakers, marking a dramatic uptick in advertising and promotion enforcement compared to recent years. (RELATED: FDA cracks down on drug ads, promises to end adequate provision ‘loophole’, Regulatory Focus 10 September 2025)

Earlier this month, the agency included a proposed rule to end adequate provision and require a detailed “brief summary” of side effects in broadcast advertisements in its latest unified agenda. The proposed rule is slated to be issued by December 2026, though the agency does not always adhere to the timetables specified in the unified agenda. (RELATED: FDA plans rules to rein in drug ads, enable proactive release of CRLs, and more, Regulatory Focus 8 July 2026)

In its announcements, FDA said that adequate provision has been misused to conceal critical safety risks in both broadcast and digital advertisements, leading to inappropriate drug use and undermined public trust.

Rule would shut down drug advertising

Jason Cober, senior consultant for regulatory affairs at Compliance Forward, stated that such a rule, if implemented, would have a chilling effect on drug advertising. Cober previously served as the lead project manager for the FDA’s Office of Prescription Drug Promotion (OPDP) for 18 years.

“At a high level, they say in the agenda that this isn’t a ban on DTC advertising but at the same time the net result would be that for most companies, the safety profiles for most of these products would prevent them from presenting the brief summary within the brief confines of a standard ad block, whether it is 30 or 60 or 90 seconds. While it might not necessarily be an outright ban, it will be very difficult for companies to fit that information in their TV ads,” Cober said.

He further noted that “if you have a very small risk profile, you might be able to fit it in, but for most companies, it would be prohibitive,” referring to the cost of airing longer ads.

Jeff Greenbaum, managing partner of Frankfurt Kurnit, concurred. “I think that a rule change like this will dramatically change the landscape of direct to consumer advertising in the United States. This is not just a small change. This isn’t just a change that advertisers can just tweak what they’re doing, it will not be business as usual,” he said. “The intent behind this rule change is to essentially make most DTC ads impossible. I think that the kinds of drug ads that you see on TV are going to end.”

Greenbaum added that drug companies would have to fundamentally change how they market their products. “There has been a whole industry built up around supporting the marketing of prescription drugs. There are advertising agencies that specialize in drug advertising.”

“I think that this has the potential to be an enormous shift in how the whole pharmaceutical drug ecosystem looks,” he said.

Mark Gardner, founder and managing partner of Gardner Law, said that if implemented, the rule would make prescription drug advertising “commercially impracticable through excessive disclosure requirements, and could run afoul of the First Amendment.”

To justify its actions, he said, FDA would need to provide a valid reason for suppressing lawful and non-misleading commercial speech. Additionally, FDA would have to demonstrate that the restrictions imposed are not broader than necessary. This requirement must be fulfilled to meet the standards set by Central Hudson Gas & Electric Corp. v. Public Service Commission.

Expect a challenge

Joshua Oyster, an attorney with Ropes & Gray, stated that his firm has been working with many pharmaceutical companies over the past year in terms of navigating the shifts in direct-to-consumer advertising and the crackdown last September.

Oyster stated that if the rule is published, the agency should anticipate significant opposition from the industry.

“What this sets up is that if the administration were to pursue a proposed rule, there would be significant pushback from the biopharmaceutical industry and advertising associations and broadcasters. They would argue on the First Amendment. Even though the administration is saying this isn’t a ban, in effect the arguments will be that this results in a de facto ban,” he said.

Oyster added that “FDA will have a difficult time defending a proposed rule that looks like a de facto ban, and you will have a tough time defending that on First Amendment grounds.”

He said he also expects to see challenges under the Administrative Procedure Act because the action may be viewed as “arbitrary and capricious” and requiring full summaries of ads may “detract from and make it more difficult for consumers to comprehend.”

FDA acknowledges in the unified agenda that this rule would have a significant cost for industry, Oyster noted. “This plays into the costs here. They are choosing not to advertise because it is not economically feasible to do so, and this brings up First Amendment arguments.”

Oyster also noted that it’s unclear whether the agency will follow through with issuing the proposed rule. “There is still a long way to go,” he said.

Rule would reverse long-standing policy

Cober said that FDA’s announcement would turn back decades of policy on DTC advertising. Beginning in the 1990s, consumers advocated for a more active role in their health care decision-making and believed a less-is-better approach to such advertisements.

Cober said that “in general, we saw this shift in the late 1970s and the 1980s that started this change, it was full steam in the 1990s where people want to take a more active role in their health care decision-making. This is one of the reasons why FDA wanted to provide guidance to industry on how they can meet the adequate provisions.”

He cited a 2018 study by FDA staff which found that including a disclosure to inform consumers about where to find additional information on medications “did not adversely affect consumers' processing of drug risk and benefit information.” The research further found that “including a disclosure alerting consumers that not all risks are presented may be an effective strategy.”

Cober noted that “generally speaking, the brief summary statements were better comprehended by consumers.”